Elanco Animal Health Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.5%projected annual EPS growth
Analyst Coverage
14analysts covering
FY Revenue (est.)
$5.1Bnext fiscal year
FY EPS (est.)
$1.13next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Constant Currency Revenue Growth Quarterly1,000.0%Target: 5% to 7%
Innovation Revenue Quarterly287M
Net Leverage Ratio Quarterly3.5xTarget: 3.0x to 3.2x
Watch Items
- Zenrelia and Credelio Quattro Market AdoptionTrigger: Deceleration in market share gains or negative label updatesAction: Re-evaluate peak sales potential and adjust R&D/marketing spend allocation.
- Refinancing and Interest Rate ExposureTrigger: Net leverage remaining above 3.5x or rising debt service costsAction: Accelerate debt paydown using free cash flow and optimize capital structure.
Research as of 2 Sep 2026